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Abstract: Adjustable gastric banding (AGB) is quickly becoming the most popular bariatric 
operation performed in the United States and Canada. Patients are particularly fond of the sim-
plicity of the tool, the relatively low morbidity of the surgery, the quick recovery, and overall 
results. The gastric band has evolved over its 35-year history into a very successful adjustable tool 
used to restrict food consumption and limit caloric intake. The percent of excessive weight loss 
after banding can range from 30%–60% and depends on the time out from surgery. Along with 
weight loss, there is good resolution of the co-morbid conditions that are associated with excess 
weight and improvements in quality of life demonstrated after banding. Nutrition and follow 
up are extremely important after banding to ensure good compliance and adequate weight loss. 
Failure to follow the postoperative diet, exercise regiment, or mechanical failure of the band can 
lead to failure to lose adequate weight. While there are particular early and late complications 
associated with this surgery, the safety profile of the AGB is very appealing when compared to 
other bariatric operations. As we continue to reduce the morbidity of the procedure, the simple 
adjustable band concept has a lot of potential to remain a primary technique of maintaining long 
term weight loss. In conclusion, AGB has and continues to play an important role in the treat-
ment of morbid obesity. It offers reasonably good weight loss results with very little morbidity, 
and the future of the adjustable band is bright.
Keywords: adjustable band, gastric, bariatric, operation, surgery, weight loss, lap-band
Introduction
While gastric bypass surgery has been at the forefront of weight loss surgery since the 
1960s, adjustable gastric banding (AGB) is quickly becoming the most popular proce-
dure performed in the US and Canada. Of the 220,000 bariatric operations performed 
in the US and Canada last year, 42.3% were an AGB operation, which is an increase 
from the 24.4% five years ago, while the percentage of gastric bypasses decreased from 
65.1% to 49.0% over the same time period.1 Clearly, there is a substantial US market 
for AGB, and patients are particularly fond of the simplicity of the tool, the relatively 
low morbidity of the surgery, the quick recovery, and overall results.
This review is intended to give an unbiased view of the role that gastric banding 
has played in the treatment of morbid obesity. Therefore, it will address the history of 
banding and discuss the evolution of this restrictive procedure. Bringing us to modern 
day banding, we will scrutinize the short-term weight loss result and how weight loss 
is maintained during the intermediate time period. Long-term weight loss results are 
examined, and the band’s ability to resolve comorbid conditions related to excessive 
weight and its effects on patient quality of life are discussed. A substantial change in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 56
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the patient’s behavior with food and a strict diet is a must 
for good results, and the nutritional considerations after 
banding are discussed. Complications and failure rates are 
scrutinized with respect to the low morbidity and mortality 
of AGB. Finally, results with AGB are compared with other 
weight loss operations, and we look into the future prospects 
of AGB.
History and types of gastric banding
Origins of the nonadjustable band
In the summer of 1974, after becoming “disenchanted” with 
gastric bypass procedures for the treatment of morbid obesity 
and its complications, a Dr Wilkinson began to experiment 
with limiting caloric intake and increasing early satiety by 
decreasing the reservoir capacity of the stomach. However, 
his goal was to accomplish this while maintaining the normal 
continuity of the gastrointestinal tract. Dr Wilkinson inverted 
the lesser curvature into the greater curvature of the stomach 
and then wrapped the entire stomach with polypropylene 
mesh. In 1976, he reported combining this procedure with 
a Nissen fundoplication to prevent reflux and achieving 
satisfactory weight loss in 99 of 100 patients.2
In 1978, Drs Wilkinson and Peloso changed the procedure 
by placing a 2 cm polypropylene mesh around the upper part 
of the stomach.3 In the US, Europe, and Australia, surgeons 
were implanting not only polypropylene mesh bands but 
also Dacron, silicone-covered, and GORE-TEX® meshes.4–7 
A special polypropylene clip was also used for restriction.8 
Difficulty in achieving proper restriction, food intolerance, 
and emesis because of stenosis of the gastric pouch outlet, 
band displacement, band erosion, esophagitis, and Barrett’s 
esophagus necessitated reoperation for band correction or 
removal with conversion to vertical-banded gastroplasty for 
many of these early procedures. In 1994, despite initially 
having successful weight loss with nonadjustable mesh band, 
Naslund et al reviewed their 12-year data which revealed that 
this procedure was fraught with complications over the time 
period of the study; specifically, only 31% of patients had an 
intact band in their long-term data.9
Logical step of adjustability
Considering the complications of nonadjustable gastric 
  banding, two pioneers began to work on the ingenious con-
cept of adjustability. In the mid-1980s in Innsbruck, Austria, 
a surgeon named Szinicz and his colleagues began placing 
silicone gastric bands in animals and called the procedure 
“reversible gastric banding”. He saw the potential in changing 
the degree of gastric restriction over time.10
Likewise, another surgeon named Lubomyr Kuzmak, 
a Ukrainian immigrant to the US, also recognized the poten-
tial of adjustability and the tolerability of silicone. In 1986, 
he reported on the implantation of adjustable silicone gastric 
bands in humans, and described better results with adjustable 
silicone bands compared with the nonadjustable silicone band 
he had been using since 1983.11 His band was less invasive to 
the stomach, was adjustable, and also reversible.12
Laparoscopy
Surgeons and scientists now had the concept and materials 
for success. Fortuitous in the late 1980s was the advent of 
laparoscopy, and it seemed only reasonable to convert this 
previously open procedure to a laparoscopic procedure 
to decrease perioperative morbidity and mortality and to 
increase its attractiveness to patients. Broadbent et al in Aus-
tralia and Catona et al in Italy reported on the laparoscopic 
placement of nonadjustable gastric bands in February and 
May 1993, respectively, and the latter group realized that 
stenosis of the gastric pouch outlet was a major problem with 
these bands.13,14 A few surgeons saw the potential of Kuzmak’s 
adjustable band and in 1993, the first laparoscopic adjustable 
silicone gastric band was placed in a human by Belachew et al 
in Huy, Belgium. They had been successfully placing adjust-
able silicone gastric bands laparoscopically in animals for 
two years prior and, in 1998, reported the efficacy of adjust-
able silicone gastric banding compared with vertical-banded 
gastroplasty.15 In the meantime, surgeons began training to 
place the laparoscopic adjustable silicone gastric band and 
in July 1994 the LAP-BAND® system (Allergan Inc., Irvine, 
CA) became available. The Food and Drug Administration 
(FDA) approved clinical trials in selected centers in the US 
in 1995. Finally, in 2001, the LAP-BAND obtained FDA 
approval and has since been become an important surgical 
treatment for morbid obesity.12
Market today
There have been several modifications to the laparoscopic 
adjustable silicone gastric band since approval of the LAP-
BAND system in 2001. Four versions of the adjustable gastric 
band now exist worldwide.
The two US-approved bands are the LAP-BAND system 
and the REALIZE® band (Ethicon Endo-Surgery Inc., Johnson 
and Johnson, New Brunswick, NJ). The LAP-BAND is a 
low-pressure, silicone band that uses Omniform® technology 
comprising soft, precurved, and individual sections that create 
a 360° inflation area to prevent creases or folds that may lead 
to band damage. The two types are the AP standard and AP Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 57
Adjustable gastric banding for obesity Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
large. The REALIZE band AGB-C is the Johnson and Johnson 
version of the Swedish Band. It is a low-pressure, silicone band 
made to be one-size-fits-all. The rationale for this band is that 
a balloon not under high pressure is able to conform to tissue 
more easily than a band under high pressure.
Two laparoscopic adjustable silicone gastric band 
  companies make bands for use in Europe, ie, MIDBAND® 
and Helioscopie. The MIDBAND is a low-pressure, silicone 
band also in use in Latin America as well as in Europe. 
The French company Helioscopie makes several versions of 
the HELIOGAST® band in different sizes with three different 
ports. Several other bands are still in existence and in circula-
tion, and there are some bands made only for limited markets; 
however, the MIDBAND and the Helioscopie are the major 
gastric bands produced and marketed in Europe today.
Results of laparoscopic adjustable 
gastric banding
Short-term weight loss
The main reason AGB has gained more market share in the 
arena of bariatric surgery around the world is the equitable 
results in weight loss without the morbidity of the laparo-
scopic roux-en-Y gastric bypass (LRYGB). However, around 
the world, results are reported in different ways. Most pro-
grams report their results as percentage of excess weight lost 
(%EWL) although there are other measurements of success, 
ie, percentage of body mass index (BMI) lost, reduction in 
BMI, improvement in obesity-related medical illnesses, and 
improvement in other quality of life (QoL) indicators. What 
these alternative categories lack is an adequate duration of 
followup for the results reported. Most of the comparative 
literature in bariatric surgery is retrospective data over a short 
time period, usually two to three years. The US literature also 
lags behind the rest of the world because of the late adoption 
by the FDA (1992 versus 2001) of the LAP-BAND and now 
(1994 versus 2007), the REALIZE band. Therefore, long-
term data in the US is extrapolated from the placement and 
followup of these bands in Europe, Asia, and Australia.
Longer followup is possible in places like Europe because 
of surgical services being provided by a national health-
care service with followup in a nationally enrolled patient 
program across a smaller geographic area. The short-term 
post-surgical weight loss time frame is generally regarded 
as less than three years. Short-term has also been broken 
down into six months, one year, 18 months, two years, and 
then three years in various studies.16–20 These results set the 
realistic expectations for patients, but they also can show 
slow, sustained weight loss with laparoscopic AGB with 
time, as opposed to quicker weight loss in the first year with 
the LRYGB.
There are several small and large studies which show a 
variation on the results above, but these numbers are consis-
tently validated across the world (see Figure 1).
Long-term weight loss
Longer followup has been reported up to 12 years,16 but it is 
sparse in the US literature. Long-term time frame is measured 
at more than three years after surgical intervention. Most 
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Figure 1 Percentage excess weight loss results for the adjustable gastric band over years out from surgery.16–21
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long-term data is from Europe because of the more robust 
followup in Europe as a result of the National Health Service 
and its ability to track a less mobile population over a smaller 
geographic area. American studies have an average followup 
of about 50% versus about 90% in Europe.16,18 The long-term 
weight loss results are shown in Figure 1.
Other factors influence sustained weight loss over the 
long term. One is the presence of comprehensive weight 
loss centers versus only surgical followup for adjustments. 
The other factor is the existence of support groups which 
are helpful after the initial weight loss has occurred. More 
parameters are being measured to help understand adher-
ence to lifestyle change through the years. Reaching realistic 
weight loss expectations, improvement in comorbidities, and 
cumulative QoL surveys are being collected to show why 
there is a variance in long-term data from different centers 
and between areas of the world.
Resolution of comorbid conditions
Along with weight loss, bariatric surgeons want to measure 
resolution of comorbid conditions that are associated with 
excess weight. Most research shows an improvement in 
Type 2 diabetes22,23 (79%–81%), metabolic syndrome (78%) 
  hypertension (67%), dyslipidemia (66%), reflux (66%), asthma 
(57%), arthritis/joint pain (70%), polycystic ovary syndrome 
(48%), and depression (57%).23–25 Unlike the metabolic effects 
seen with bypass procedures such as gastric bypass and duode-
nal switch, the remission or improvement in conditions such as 
Type 2 diabetes and metabolic syndrome after AGB is believed 
to be because of the direct effects of weight loss. Therefore, 
the time required to see improvement in these conditions can 
vary substantially, and is dependent on the amount of weight 
loss. In our own cohort of 342 gastric banding patients we 
found a correlation between weight loss and improvement in 
comorbid conditions (r = 0.90). This result was anticipated 
and is logical. If the excess weight causes the conditions, they 
should resolve with the loss of the excess weight.
Changes in quality of life
There have also been improvements in QoL demonstrated 
after banding, using many methods including the Short 
Form-36 Health Survey (SF-36).23–25 Nonetheless, there 
is no consensus on QoL tools that should be used, nor 
if the results are lasting. There definitely seems to be a 
“honeymoon” phase of improvement in QoL for patients, 
but there seems to be a drift downward in their scores after 
this. We have demonstrated this using the Moorehead-
Ardelt Quality of Life Questionnaire-II over a three-year 
period in 342 AGB patients. The significant improvement 
in QoL lasted for approximately 15 months and then 
dropped below statistical significance for the rest of the 
study period (see Figure 2). QoL did not correlate with time 
since surgery (r = −0.33), nor did any of its components. 
Furthermore, there was no correlation of QoL with weight 
loss or resolution of comorbid conditions (R = −0.02 and 
0.18, respectively).
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Figure 2 Shows the best fit line for the quality of life score. The upper critical value (UCV) and lower critical value (LCV) are drawn to represent the values of the mean that 
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Maintenance
Followup
Laparoscopic AGB is an effective weight loss procedure, with 
the majority of patients losing between 44% and 55% of their 
excess body weight.26 Typically this technique results in a 
slower weight loss than LRYGB, with %EWL stabilizing over 
a four-year time frame.27 However, there are many factors that 
influence weight loss results seen with banding. Not only is 
the surgical technique of band placement important,28 but also 
close patient followup with band adjustments is essential in 
achieving successful weight loss.29,30 Band adjustments typi-
cally begin one month after surgery, with further monthly 
adjustments during the first six months, and usually restriction 
is achieved. Frequent visits are expected, for example every 
three to six months, to ensure ongoing compliance and weight 
loss. Thereafter followup should occur as needed based 
on restriction, weight loss, and potential complications.31 
Suboptimal followup of the patient may contribute to poor 
outcomes. Shen et al demonstrated that patients who were 
seen in clinic six times or more after gastric banding had a 
significantly greater reduction in %EWL than patients who 
returned less frequently.32 Patient motivation as well as sur-
gical team support is needed to achieve optimal weight loss 
after banding. In addition, nutritional education and dietary 
compliance are likely to be the most important elements for 
achieving successful weight loss and maintenance.
Nutrition
The adjustable gastric band is a purely restrictive bariatric 
procedure. The gastrointestinal tract is not altered and mal-
absorption of nutrients is not a feature of this procedure. 
Success of the adjustable gastric band surgery in promoting 
weight loss is based on the patient consuming a lesser volume 
of food that will promote a sense of early satiety because of 
a restricted proximal gastric pouch size.
Banding requires that a patient make dietary and behav-
ioral adjustments to cope with their changed gastric ability.33 
High-risk eating habits such as grazing, and emotional or 
mindless eating should be avoided because these behav-
ior traits will hinder weight loss.34 The patient must be an 
active participant in helping to create a proper stoma size by 
monitoring the volume of food they consume until they feel 
satiated and there are changes in their weight status. Appro-
priate band-fill adjustments will facilitate weight loss and 
preserve esophageal integrity. If a band is filled too tightly, 
the patient may experience signs of heartburn, regurgitation, 
and esophageal irritation.35
Volume restriction on the amount of food consumed 
places all gastric banding patients at risk of nutrient compro-
mise.36 More prevalent nutritional deficiencies following AGB 
placement include those of iron, folate, thiamine, vitamin 
B12, and vitamin D.37 Supplementation with a multivitamin 
and mineral compound and assessment of nutritional and 
metabolic parameters on a regular basis can help to prevent 
nutritional compromise following ABG placement.38,39 Large 
supplement tablets may not be tolerated because of a restricted 
gastric stoma size. Adult chewable or liquid multivitamin and 
mineral preparations will be better tolerated because they can 
easily pass through a narrow gastric stoma.
An example of the nutritional information given to 
banded patients would be as follows:
•    Liquids should be zero calories and noncarbonated: 48–64 
ounces should be consumed daily to maintain adequate 
hydration status.
•    Soft foods that can slip and slide past the AGB will not help 
signal satiety or control physical hunger, and should be 
avoided. These foods include cream soups, yogurt, chips, 
crackers, pretzels, ice cream, shakes, and smoothies.
•    Solid foods will help to create a sense of satiety and full-
ness, eg, chicken, ground beef, fish, seafood, turkey, pork, 
lean sliced deli meat, and low fat cheese.
•   Avoid fatty and greasy foods; instead bake, broil, steam, 
grill, or roast foods.
• Avoid cream and butter sauces.
•    Separate liquids and solids, and drink 30 minutes before 
or after a meal.
•    Consume three meals daily, limiting meal times to 
30 minutes. This will help to confer a sense of satiety 
and avoid the pitfalls of grazing or munching on food in 
between meals.
•    Snack only if hungry, limiting snacks to 150 calories. 
Do not turn snacks into mini meals.
•   Avoid grazing, and mindless or emotional eating. These 
are high-risk eating habits that can promote weight plateau 
or weight gain.
Maximizing postoperative weight loss success can be 
obtained by making long-lasting nutritional lifestyle changes. 
The dietitian’s role in the preoperative and postoperative 
diet education process and reinforcement of behavioral 
compliance is crucial to a sustained weight loss and healthy 
outcome.40
Without reasonable expectations, good followup for 
adjustments, adequate education on life style, and dietary 
modifications needed for success, then failure to lose ade-Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 60
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quate weight after AGB is a real possibility that may lead to 
high conversion rates to other procedures.
Failure rates
As a result of the rigorous followup and dietary changes 
needed, the AGB has the greatest variation in its level of 
success. Currently, there is no consensus of a formal defini-
tion of failure, but most definitions reported focus around a 
failure to achieve a satisfactory %EWL or a certain reduction 
in BMI.
Failure rates in the first several years after surgery range 
from 10%–20%, with greater failure rates occurring the 
longer the band is in place. In Finland, where they have a 
longer experience with the low-pressure systems we use 
in the US, failure to achieve 25% EWL is reported in 15% 
of patients during the first one to three years, and with an 
increase in failure rate of 40% during the eighth and ninth 
postoperative years.41 In Sweden, where the same banding 
systems are utilized, a report of 824 patients with an average 
preoperative BMI of 43 kg/m2 demonstrated a 5% reoperation 
rate secondary to insufficient weight loss.42
In the US, similar failure rates are seen. A study from 
Irvine Medical Center where 250 patients were randomly 
assigned to gastric bypass versus gastric banding reported 
that 16.7% of patients in the gastric banding arm failed to 
achieve 20% EWL.20 Of 484 patients at the University of 
Texas Medical School in Houston, 15% failed to achieve 
30% EWL at one year.43 Smaller studies across the US report 
similar failure rates.44,45
It is difficult, if not impossible, to predict which patients 
will or will not have poor weight loss after an AGB operation. 
Snyder et al showed a positive correlation between BMI and 
failure rates. Their conclusion suggests that patients with a 
BMI greater than 46 kg/m2 are at high risk of failure to lose 
sufficient excess weight one year after AGB surgery.46 Other 
studies identified male gender and African-American race as 
risk factors for failure.20,45
Comparison of banding  
with other bariatric procedures
A recent Cochrane review compared AGB with conventional 
weight loss protocols and several other bariatric procedures.47 
Three trials reported their findings on conventional therapy 
versus adjustable gastric banding.48–50 At two- to three-
year followup, there was documented statistical benefit in 
weight loss in the surgical arm versus conventional therapy. 
In addition, randomized controlled trials including indi-
viduals with Type 2 diabetes reported a higher resolution 
rate and improvements in metabolic syndrome at two years. 
A 10-year study found a statistically significant improve-
ment in comorbidities of patients who underwent gastric 
banding.
On the other hand, comparing AGB with other bariatric 
procedures has shown some benefit in performing the 
other bariatric procedures.12 Agrisani et al52 report that one 
advantage of LRYGB compared with AGB is better long-
term (five year) weight loss. On the other hand, AGB was 
shown to have a shorter operative time, fewer complications, 
and fewer reoperation rates.
Vertical gastric banding versus AGB was reported in 
three studies.53–55 In these studies, there were missing out-
come data and inconclusive weight loss results. In one study, 
a statistical difference was reported in operative times and 
duration of hospital stay in favor of AGB.
One study on sleeve gastrectomies versus AGB reported 
an improvement in comorbidities and lower late complication 
rates in patients undergoing sleeve gastrectomies, however, 
sleeve gastrectomies had more early postoperative 
  complications.56
A retrospective comparison of biliopancreatic diversion 
versus AGB reported better weight loss with biliopancreatic 
diversion.59 However, biliopancreatic diversion patients had 
longer hospital stays and higher complication rates that those 
who had AGB. Both procedures resulted in similar resolution 
of comorbidities.
In conclusion, AGB has been proven to be of more 
benefit than medical weight loss therapy. However in 
comparison with other bariatric procedures, AGB has its 
advantages and disadvantages. Although multiple studies 
have been undertaken comparing AGB with other bariatric 
procedures, more statistically qualifying trials are need 
for validation of one procedure over another. It appears 
that weight loss with AGB is not as good as the other 
procedures offered; however, the morbidity and mortality 
of the band is very attractive to many patients as well as 
to many surgeons.
Complications of laparoscopic AGB
While the morbidity and mortality of laparoscopic AGB are 
typically lower than that of the more invasive laparoscopic 
bariatric stapling procedures, there are still several well-
described complications specific to gastric banding that 
may lead to a significant reoperation rate. The number of 
AGB procedures is increasing in the US, and every surgeon 
who manages patients with morbid obesity must be able to 
recognize and manage these complications.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 61
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The overall complication rate for laparoscopic AGB 
ranges from 12% to 48%, with larger series reporting a 
complication rate of about 20% to 25%.59–72 The complica-
tion rates in more recent studies are generally lower than in 
older studies. This may be attributable to improved surgical 
techniques and the development of newer band designs.61 
With this complication rate, there is also a significant reop-
erative rate ranging from 10% to 34%, depending on the 
series reviewed.
Most complications occur late, rather than early. While 
most series report no mortality, the rare deaths that have 
been described are primarily because of pulmonary embo-
lism and myocardial infarction. This is a reminder of the 
significant morbidity associated with this patient popula-
tion. Therefore, the importance of perioperative deep vein 
thrombosis prophylaxis and preoperative cardiac evaluation 
when appropriate on all patients undergoing bariatric sur-
gery regardless of the type of operation, cannot be stressed 
enough.58
Early complications
Early complications include band obstruction, gastric perfo-
ration, wound infection, and bleeding.59,60 Careful surgical 
technique is essential in limiting these early complications. 
Meticulous dissection should be undertaken during the cre-
ation of the retrogastric tunnel so that the chance of a gastric 
perforation or injury to the spleen is minimized. A gastric or 
esophageal injury may lead to aborting of band insertion and 
a splenic injury may prompt an emergency splenectomy. In 
the majority of cases, band obstruction may be managed con-
servatively, but if symptoms do not resolve, re-exploration 
may be necessary. At surgery, removal of the proximal gastric 
fat pad may be all that is required to relieve the obstruction. 
In other situations, replacement of the device with a larger 
size band may be necessary.
Late complications
Late complications include band slippage, pouch or 
esophageal dilatation, band erosion, and port/tubing 
  complications.59–70 Band slippage or band prolapse occurs 
when part of the stomach herniates through the band at the 
top of the stomach. This occurs in about 4% (1.0%–6.5%) 
of patients in recent studies, with older studies showing a 
much higher rate of this complication.64,65,71–73 The reason 
for this dramatic reduction in slippage rate is attributed to 
the use of the pars flaccida technique instead of the less 
frequently used perigastric approach for the insertion of 
the gastric band around the proximal stomach. Several 
studies have demonstrated a reduction in the number of slips 
from as high as 15% down to 2% simply by this change of 
technique.74
Patients may present with vomiting and dysphagia, some-
times to the point of being unable to handle their own oral 
secretions. Other symptoms include reflux and inadequate 
weight loss. Abdominal pain is rare but, if present, should 
alert the surgeon to the possibility of gastric ischemia.75 One 
should also consider the presence of an unrecognized hiatal 
hernia in these patients. Parikh et al demonstrated that nearly 
one-third of patients presenting with a band prolapse had a 
hiatal hernia found during reoperation,59 underscoring the 
importance of identifying and repairing any significant hiatal 
hernias during initial band insertion.
When a patient presents with these symptoms, the band 
should be fully deflated. If symptoms persist, a slip or gas-
troesophageal dilatation should be strongly suspected, and a 
gastrografin or barium swallow should be obtained. Definitive 
treatment for gastric prolapse involves surgery. A laparo-
scopic exploration should be performed to reduce the pro-
lapse and/or to remove or reposition the band. The placement 
of an anterior gastrogastric fixation suture may also help limit 
the number of band slippages.
Gastroesophageal dilatation has a similar presentation 
to band prolapse. Heartburn, nocturnal reflux, dysphagia, 
and vomiting may occur. The incidence of gastroesophageal 
dilation ranges from about 5% to 15%. Reasons for pouch or 
esophageal dilation may be related to overtightening of the 
band or malpositioning of the band, which is typically too 
low. As with band slippages, pouch dilation may be related 
to the presence of an unrecognized hiatal hernia and should 
be investigated.59 An evaluation for esophageal dysmotility 
may also be warranted in these patients; however, preopera-
tive manometry may not be predictive of the development 
of postoperative esophageal dysfunction.72 Management 
of this complication typically entails deflation of the band 
and dietary modification, with observation of symptoms 
and followup contrast studies. In the majority of patients, 
the dilation resolves within six weeks.75–77 Subsequently, 
cautious adjustments can be performed. If the dilation does 
not resolve with conservative management then surgical 
intervention may be required. Removal of the band is rec-
ommended because there are several long-term deleterious 
effects of esophageal dilatation, as described by DeMaria 
et al.78 When the band is removed, strong consideration 
should be given to conversion to a gastric bypass or sleeve 
gastrectomy because many patients will regain weight after 
the restriction is removed.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 62
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Band erosion may be considered one of the most serious 
complications of AGB. The incidence ranges from 1% 
to 3% depending on the series. The occurrence of ero-
sions seems to have decreased in more recent times with 
the advent of newer band designs that have a high-vol-
ume,63–65,69,71 low-pressure system, and improved surgical 
techniques.61,69 Band erosion may occur as a result of a 
tight fundoplication, particularly if the buckle of the band 
is covered. The buckle may act as a lead point for the ero-
sion. Care should be taken at the initial operation to avoid 
covering the buckle. Other factors that may play a role in 
band erosions include serosal injury during insertion, use 
of nonsteroidal anti-inflammatory agents, increased pres-
sure within the band, and excessive vomiting.71,79,80 Any 
patient who presents with a late port site wound infection 
should be investigated with an upper endoscopy to rule 
out intragastric band migration, as this is a well-described 
presentation for this complication. Other symptoms may 
include sudden weight regain, abdominal pain, bleeding, 
or peritonitis. The management of patients with erosions 
involves endoscopy with potential intraluminal retrieval 
of the band or a laparoscopic removal of the band, with 
suture repair of the stomach at the site of the erosion.61,80 
Whether a conversion to another procedure is done at the 
time of band removal is surgeon-specific, but most sur-
geons would simply remove the infected band. Certainly, 
placement of another band at the time of removal would 
not be advisable because of the assured risk of infection 
and recurrent erosion.
Port and tubing issues occur in about 5% of patients, 
but may account for up to 11% in larger series with longer 
  followup.63 These complications include saline leaks from the 
tubing or port, displacement of the port in the subcutaneous 
space, and port site infections. Port issues usually require 
some type of surgical intervention. For port site infections, 
it may be necessary to remove the port with delayed replace-
ment of the reservoir once the infection has cleared. All 
late port site infections should prompt an investigation for 
intragastric band migration, as previously discussed. Strict 
adherence to good sterile technique is extremely important 
and will help limit these complications. Improvements in 
port design have helped reduce band leaks that occur because 
of inadvertent puncture of the tubing as it enters the port 
in the subcutaneous pocket during band fills. Fluoroscopy 
may aid in performing fills in patients who have a port that 
is difficult to access. A water-soluble contrast study may 
help identify the location of a suspected leak in patients who 
have a port volume discrepancy.61 Port fascial fixation is also 
very important and adequate fascial bites should be taken to 
prevent port migration or rotation.
Future of adjustable gastric banding
The progress of AGB over the past two decades has been 
rapid. The ease of band placement and relatively safe early 
outcomes have allowed banding to become a very popular 
option for patients desiring bariatric surgery. However, 
longer term followup has shown that adjustable gastric band-
ing can result in complications of band slippage, erosion, 
or dilation of the gastric pouch or esophagus, as discussed 
earlier.
The causes of slippage, erosion, or dilation has not been 
agreed upon by the bariatric surgical community, but a com-
monly agreed cause is chronic over-adjustment. Chronic pres-
sure on the esophagus or upper gastric pouch from a tightly 
adjusted band is likely to be detrimental at these sites. So the 
future of banding is likely going to focus on preventing or 
controlling bands from being over-tightened.
One future means of over-tightening is the implementation 
of new adjustment strategies. Use of routine scheduled 
  fluoroscopy for adjustments is not new but implies a method 
of seeing pouch or esophageal dilation earlier and intervening 
to prevent progression of dilation.17 A commonly discussed 
option that has received early study is use of pressure 
  monitoring of the band during adjustments to determine 
optimal pressures which could prevent over-tightening.81 
Bands that could monitor pressure continuously and adjust 
automatically to high pressure effects would be potentially 
valuable.
Self-adjusting bands are a reasonable possibility in the 
future. Imagine a band with a reservoir of fluid, instead of 
just a port and a computer-driven pump, that could be con-
trolled wirelessly and alter band adjustment by designated 
parameters. Such a “smart” band could monitor pressure and 
deflate automatically during times of severe obstruction. The 
band could tighten to stop a patient from eating after a certain 
amount of time. It could unfill when a patient lies down to 
sleep to prevent saliva pooling and aspiration at night. Just 
the act of periodically relaxing the band on a frequent basis 
for a small amount of time might help prevent excessive 
progressive pressure on the stomach and esophagus.
As we look further into the future, the “smart” band 
concept could expand substantially. The use of a hydraulic 
system with a port could be replaced with a portless hydraulic 
system or another mechanical system which would require 
no balloon and no fluids, possibly achieving more flexibility 
in remote adjustments as well as durability. Endoluminal Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 63
Adjustable gastric banding for obesity Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
placement of these devices would also be very attractive to 
patients who increasingly want fewer incisions or no incisions 
without compromised efficacy. Looking forward, the simple 
adjustable band concept has a lot of potential to be a primary 
technique for maintaining long-term weight loss.
Conclusion
The idea of restricting caloric intake by gastric banding has 
been around for 35 years. It has undergone many modifica-
tions to improve its safety and efficacy and is continuing 
to evolve to meet the needs and demands of patients and 
surgeons who are battling morbid obesity.
Compared with other procedures such as LRYGB, sleeve 
gastrectomy, or biliopancreatic diversion, the AGB does not 
offer as much weight loss. However, it is the safety profile that 
is so appealing to the patients. Most complications of AGB 
are not life-threatening and can be managed non-operatively 
or laparoscopically. Most of these complications can be 
avoided by good surgical technique and attention to detail 
during the original operation. With its safe track record and 
the reported average weight loss of about 50% EWL over 
two to three years, the AGB is very attractive.
However, as AGB matures in the literature, we are seeing 
significant weight regain, with %EWL falling under 40% 
by 10 years. This may result in high rates of band removal 
or revision surgery. It is difficult to assess which patients 
will do better than others when evaluating patients for AGB 
surgery. Certain characteristics, like high starting BMI, 
may indicate the potential for less than optimal weight 
loss results.
As with all weight loss operations, the patients must 
continue life-long followup with their physician’s office 
and remain devoted to good nutrition and exercise in order 
to maintain their weight loss. It is important that patients 
are constantly reminded that the band acts as a tool to help 
them lose weight and that it is imperative that they continue 
to use this tool correctly. To date, there is no “cure” for 
morbid obesity.
In conclusion, AGB continues to play an important role 
in the treatment of morbid obesity. It offers reasonably good 
weight loss results with very little morbidity, and the future 
of the adjustable band is bright.
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